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ABSTRACT
First-trimester screening between 11 + 0 and 13 + 6 weeks
with qualified prenatal counseling, detailed ultrasound, bio-
chemical markers and maternal factors has become the basis
for decisions about further examinations. It detects numerous
structural and genetic anomalies. The inclusion of uterine
artery Doppler and PlGF screens for preeclampsia and fetal
growth restriction. Low-dose aspirin significantly reduces the
prevalence of severe preterm eclampsia. Cut-off values define
groups of high, intermediate and low probability. Prenatal
counseling uses detection and false-positive rates to work
out the individual need profile and the corresponding deci-
sion: no further diagnosis/screening – cell-free DNA screening
– diagnostic procedure and genetic analysis. In pre-test coun-
seling it must be recognized that the prevalence of trisomy
21, 18 or 13 is low in younger women, as in submicroscopic
anomalies in every maternal age. Even with high specificities,
the positive predictive values of screening tests for rare
anomalies are low. In the general population trisomies and
sex chromosome aneuploidies account for approximately
70% of anomalies recognizable by conventional genetic anal-
ysis. Screen positive results of cfDNA tests have to be proven
by diagnostic procedure and genetic diagnosis. In cases of in-
conclusive results a higher rate of genetic anomalies is detect-
ed. Procedure-related fetal loss rates after chorionic biopsy
and amniocentesis performed by experts are lower than 1 to
2 in 1000. Counseling should include the possible detection of
submicroscopic anomalies by comparative genomic hybridi-
zation (array-CGH). At present, existing studies about screen-
ing for microdeletions and duplications do not provide reliable
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data to calculate sensitivities, false-positive rates and positive
predictive values.
ZUSAMMENFASSUNG
Das Ersttrimester-Screening zwischen 11 + 0 und 13 + 6 Wo-
chen mit qualifizierter Beratung, differenzierter Organdiag-
nostik sowie maternalen und biochemischen Markern ist die
Grundlage der Entscheidung über den Umfang weiterer
Untersuchungen. Mehr als die Hälfte relevanter fetaler Fehl-
bildungen können frühzeitig erkannt werden. Erhöhte Na-
ckentransparenz und/oder auffällige biochemische Parameter
weisen auf genetische oder strukturelle Anomalien hin. Durch
Einschluss uteriner Dopplerparameter und des PlGF können
die Risiken von Präeklampsie und Wachstumsrestriktion
bestimmt und mittels der Gabe von ASS der weitere Verlauf
zahlreicher Schwangerschaften positiv beeinflusst werden.
Schwellenwerte (Cut-offs) und die Bildung von Bereichen
hoher, intermediärer oder geringer Wahrscheinlichkeiten für
das Vorliegen genetischer Anomalien dienen der Erläuterung
der Erkennungs- und der Falsch-positiv-Raten. In der Beratung
muss das individuelle Bedürfnisprofil der Schwangeren für
entsprechendes Vorgehen (keine weitere Abklärung – Screen-
ing an zellfreier DNA – diagnostische Punktion) ermittelt wer-
den. Die Beratung beinhaltet, dass in Kollektiven jüngerer
Schwangerer und altersbedingt geringer Prävalenz oder beim
Screening auf seltene submikroskopische Strukturanomalien
auch bei hoher Spezifität der positive prädiktive Wert des
Screenings gering ist. Innerhalb der Gesamtpopulation
machen Trisomien und Anomalien der Geschlechtschromoso-
men etwa 70% der lichtmikroskopisch erkennbaren Anoma-
lien aus. Nach einem positiven Screening-Befund ist eine Absi-
cherung durch diagnostische Punktion unerlässlich. Bei
Testversagen besteht eine höhere Rate pathologischer
Befunde. Die Verlustraten nach diagnostischen Punktionen
liegen in Expertenhand um 1 bis 2 auf 1000 über der natürli-
chen Verlustrate. Die Beratung sollte die Möglichkeiten der
Erkennung submikroskopischer Strukturanomalien mittels
vergleichender genomischer Hybridisierung (Array-CGH)
beinhalten. Belastbare Daten zu Sensitivität, Falsch-positiv-
Raten und positiven prädiktiven Werten beim Screening auf
Mikrodeletionen und -duplikationen lassen sich aus den
bislang vorliegenden Studien nicht berechnen.
Introduction
In 2012, one year after market introduction in the USA, the first
screening test for trisomies 21, 18, and 13 and the gonosomes
using cell-free DNA from maternal blood (cfDNA) was introduced
in Germany. The development of simpler and significantly more
cost-effective test procedures and intensive marketing resulted
in increased use. Recommendations for using cfDNA tests were
published in 2015 in the European Journal of Ultrasound [1, 2].
The cfDNA in maternal blood is largely from the mother. Only a
significantly smaller portion is from the placenta. For the purpose
of clarity, the term cfDNA is thus exclusively used here instead of
the terms cell-free fetal DNA (cffDNA) and cell-free placental DNA
(cfpDNA).
cfDNA screening, often also called NIPT (noninvasive prenatal
testing), is a screening method that always requires clarification
via diagnostic procedure in the case of abnormal findings. Com-
bined first-trimester screening, which can be combined with early
diagnosis of anomalies and preeclampsia screening (▶ Table 1)
and thus goes far beyond trisomy 21 screening has been long
established and is widely used as a screening method [3 – 5].
Approximately two-thirds of cfDNA tests in Germany are now per-
formed between 11 and 13 gestational weeks, usually after first-
trimester screening, even if cfDNA screening starting at 10 weeks
as first-line screening is being discussed.
The spectrum of the existing first-trimester screening methods
and the useful application of cfDNA tests are discussed in the
following. In particular, the elements of screening and the clarifi-
cation of abnormal findings are taken into consideration.
Elements of screening 11 + 0 to 13 + 6
weeks
Counseling prior to prenatal screening
The law on genetic testing in humans (Genetic Diagnostics Act)
[6] and the subsequent guidelines regulate the handling of genet-
ic analyses and prenatal risk clarification on the basis of aneuploi-
dy screening in first-trimester screening. The consequently estab-
lished Commission on Genetic Testing (GEKO) at the Robert-Koch
Institute creates guidelines relating to the generally accepted
state of knowledge and technology.
With respect to the Law on Patients’ Rights from 2013 [7], the
restriction to physicians in § 7 and informed consent discussion in
§ 9 of the Genetic Diagnostics Act are pivotal: Prior to obtaining
informed consent, the responsible physician must inform the
affected person of the nature, significance, and consequences
of the genetic testing. After the informed consent discussion,
the affected person is to be given appropriate time to think before
making a decision about informed consent.
GEKO defined the classification of cfDNA and the correspond-
ing counseling qualifications: In contrast to prenatal risk assess-
ment, tests of circulating placental DNA from the mother’s blood
are classified as prenatal genetic analyses for determining genetic
properties. As a result, the necessary qualifications, which can be
acquired in 72 continuing education units and the corresponding
qualification measure [8], are valid for the requirements regard-
ing competence in genetic counseling within the scope of each
medical subspecialty.
The scope of counseling with respect to the various prenatal di-
agnostic testing options has not yet been fully defined. The guide-
lines of the Federal Joint Committee regarding physician care in
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pregnancy and after birth (maternity guidelines) define the early
detection of high-risk pregnancies and births as a primary goal of
prenatal care. In addition to other medical history factors of high-
risk pregnancies, a maternal age of less than 18 years or more
than 35 years is specified in section B of the guidelines. First-trime-
ster screening and cfDNA screening are not mentioned in the
guidelines. In 2016, the Federal Joint Committee initiated an
investigation regarding the introduction of cfDNA screening and
commissioned the IQWiG to create an information brochure about
prenatal genetic diagnostic testing options (g-ba.de 2/16/2017).
In a statement regarding the analysis of fetal DNA from mater-
nal blood dated 11/12/2012, the German Society of Human
Genetics stated that due to the unnecessary consideration of the
risks of diagnostic procedures versus the probability of disease/
health problems of the fetus, cfDNA analysis should be made
available to every pregnant woman.
When providing counseling regarding primary early screening
options without a detailed fetal scan, it must be taken into consid-
eration that only trisomies 13, 18, and 21 show a significant
dependence on maternal age while structural and molecular-
genetic anomalies occur with the same rate in all age groups.
After the birth of a child with a prenatally diagnosable prob-
lem, the thoroughness of risk counseling and the presentation of
the diagnostic alternatives can be questioned. In the event of an
issue that should have been diagnosed, the physician is liable
unless it can be proven that the patient was fully informed of the
risk and all options for detection (§ 630 BGB – Law on Patients’
Rights). This is true regardless of the fact that, except for in the
case of the indications specified in the maternal guidelines, the
patient is typically responsible for the costs of first-trimester
screening, cfDNA tests, and ultrasound screening for anomalies.
Early diagnosis of anomalies
Early differentiated ultrasound diagnosis at 11+ 0 – 13+ 6 weeks in-
cluding detailed anatomical evaluation of the fetus, measurement
of the fetal nuchal translucency, analysis of the fetal and maternal
hemodynamics, and testing of various biochemical parameters in
the maternal serum helps to determine the further course of prena-
tal care. While detailed ultrasound examinations were limited to the
second and third trimesters for a long time, the first trimester has
become increasingly important for diagnosis since the 1990 s. As a
result, first-trimester screening now plays a central role in decisions
regarding further diagnostic and therapeutic measures.
The standard planes for early diagnosis of fetal anomalies have
been defined in the recommendations and guidelines of the Fetal
Medicine Foundation (FMF), International Society of Ultrasound in
Obstetrics and Gynecology (ISUOG) and the German Society of
Ultrasound in Medicine and Biology (DEGUM) [3, 9, 10].
Anatomical evaluation of the fetus makes it possible to rule out
or diagnose a series of anomalies: Syngelaki et al. [11] assigned
anomalies at 11+ 0 – 13+ 6 weeks in a population of 45 191 preg-
nancies to three categories according to their detectability
(▶ Table 2).
The detection rate of ultrasound at 11 – 14 weeks in relation to
severe anomalies is 44 % according to this study. In a German
study including 6879 pregnancies, the detection rate for detailed
ultrasound examination at an expert center was 83.7 % [12]. The
rate of severe anomalies was 1% (27/2788) in the case of an NT
< 2.5mm (2788/3094 – 90.1 %) and 19.3 % (59/306) for an NT of
> 2.5 mm. A follow-up study by the same group (n = 6.879)
showed a prevalence of severe anomalies including chromosomal
anomalies of 3.2 % (220/6858), with 50.5 % (111/220) having an
NT < 95th percentile and 49.5 % (109/220) having an NT > 95th
percentile [13]. In a meta-analysis of 19 studies including 78 000
pregnant women (prevalence of anomalies 1.2 %), the detection
rate was 51% [14]. The authors indicated that even 40% of severe
heart defects were detected early and that the combination of
transabdominal and transvaginal ultrasound allowed a significant-
ly higher detection rate (62% versus 51%).
Evaluation of the 4th ventricle, also referred to as intracranial
transparency (IT), and examination of the brain stem can result
in early detection of open spina bifida in the first-trimester exam-
ination [15, 16]. In a meta-analysis including more than 21 000
fetuses, a sensitivity of 53.5 % and a specificity of 99.7 % were cal-
culated [17].
The measurement of the fetal nuchal translucency (NT) is highly
important not only for aneuploidy screening but also for the early
▶ Table 1 Nomenclature of the screening tests in the 1st trimester.
examination ultrasound parameters serum parameters objective
first-trimester screening NT initial anomaly screening aneuploidy screening
combined first-trimester screening NT free ß-HCG
PAPP-A
combined first-trimester screening
with markers
NT, NB
DV, TRI
free ß-HCG
PAPP-A
primary or secondary clarification of the
first-trimester screening finding
contingent screening expanded screening depending on the finding of combined first-trimester screening1
early diagnosis of anomalies published quality requirements: DEGUM [10], ISUOG [9], FMF [3]
NT: nuchal translucency, NB: nasal bone, DV: ductus venosus, TRI: tricuspid regurgitation index.
1 The term contingent screening is increasingly used to refer to the use of cfDNA screening after prior risk classification based on combined first-trimester
screening.
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diagnosis of anomalies. In combination with the anatomical evalua-
tion of the fetus, the NT can indicate a number of possible diseases,
such as chromosomal and non-chromosomal syndromes, as well as
structural anomalies [18 – 22]. By combining detailed evaluation of
the fetus with measurement of the NT and secondary criteria for
the detection of trisomies 18 and 13, Wagner et al. achieved a
detection rate of 95%, which is similar to that of cfDNA [23].
Fetuses with heart defects can also have a thickened NT [11,
24] often in combination with tricuspid regurgitation and in-
creased pulsatility in the ductus venosus [25, 26]. Therefore, a
sensitivity of 57.6 % for severe heart defects is indicated for the
combination of NT measurement and the ductus venosus (one of
the two parameters > 95th percentile) [27]. However, measure-
ments of the ductus venosus and tricuspid regurgitation with a
normal NT have only low detection rates. The combination of an
NT > 95th percentile with an abnormal ductus venosus and/or
tricuspid regurgitation can increase the detection rate for severe
heart defects to > 50 % [28]. This marker screening for severe
heart defects is increasingly being replaced by the integration of
the four-chamber view and the three-vessel view into the detailed
first-trimester examination [29, 30].
In the case of monochorionic twins, the probability of a twin-
to-twin transfusion sequence (TTTS) is increased in the case of
highly varied measured values for nuchal translucency. In a meta-
analysis of 13 studies including 1991 pregnancies, discrepant NT
measurements and pathological measurements of the ductus
venosus showed a sensitivity of 52.8 % and 50%, respectively, for
the later development of FFTS [31]. Even in the case of a normal
finding, follow-up examinations every two weeks are indicated in
monochorionic twins after 14 – 16 weeks to be able to diagnose
symptoms of FFTS or twin-anemia polycythemia sequence
(TAPS) in a timely manner [32].
The probability of live birth of a healthy child can also be esti-
mated based on the NT measurement. Therefore, the probability
is 97 % for an NT < 95th percentile. It decreases in the case of a
thickened NT and is only 15% in the case of an NT ≥ 6.5mm [33].
The measurements of fetal nuchal translucency and the sec-
ondary criteria nasal bone, ductus venosus and tricuspid regurgi-
tation are the only ultrasound examinations subject to standard-
ized quality control in the form of annual reviews by the Fetal
Medicine Foundation London and the Fetal Medicine Foundation
Germany. In Germany this quality check was included in the
implementation regulations of the RKI [34, 35].
cfDNA testing should only be offered after or in connection
with professional ultrasound examination [1, 10, 36]. The signifi-
cance of early organ examination was shown by a prospective ran-
domized study in which 1400 pregnant women with a normal
finding after an expert examination between 11 and 13 weeks un-
derwent either cfDNA screening or combined first-trimester
screening according to the FMF algorithm. The false-positive rates
for trisomy 21 were 0 % for cfDNA screening and 2.5 % for com-
bined first-trimester screening [5]. The limitations of this study
are the restriction to risk calculation only for trisomy 21 and struc-
tural anatomical anomalies and the lack of biochemical param-
eters that can be useful when screening for other chromosomal
anomalies and preeclampsia.
A lack of early organ examination and the use of primary cfDNA
screening can result in structural or genetic anomalies only being
detected later.
Combined first-trimester screening (combined test)
The algorithms of first-trimester screening as a combined test of
maternal age, nuchal translucency, and the serum parameters
fßHCG and PAPP-A make it possible to calculate the probability
of the most common trisomies 21, 13, and 18 [37]. The risk algo-
rithms of the Fetal Medicine Foundation (FMF) London and the
FMF Germany are used in many countries and also allow the inclu-
sion of the indicated parameters with corresponding certification.
Combined first-trimester screening has become established as a
very good, cost-effective examination that can be performed by
most gynecologists. The detection rates at centers are 90% with
a false-positive rate of 3 – 5% [38]. 2 – 4% of pregnancies with tris-
omy 21 are identified in the low-risk group with an first-trimester
screening risk of 1:1000 or lower [37]. Approximately 85% of nor-
mal pregnancies have an first-trimester screening risk in this
range. In the high-risk group, the spectrum of possible diseases is
not limited to chromosomal abnormalities that can be detected
by cfDNA screening [4, 18].
The cut-off values for the intermediate-risk group are contro-
versial. They are characterized by the desire for an optimal combi-
nation of high detection rates both for trisomies and other genet-
ic anomalies and low false-positive rates. The higher the cut-off
value for the high-risk group, the lower the percentage of preg-
nancies in which diagnostic procedures are recommended. Every
increase in detection rate is associated with an increase in the rate
of positive findings. They are thus subject to considerations
▶ Table 2 Categories of the detectability of important anomalies at 11+0 – 13+6 weeks.
(almost) always able to be detected potentially able to be detected rarely or never able to be detected
anencephaly/exencephaly
holoprosencephaly
omphalocele
gastroschisis
body stalk anomaly
megacystis
hand and foot abnormalities
diaphragmatic hernia
lethal skeletal dysplasia
severe heart defects
spina bifida aperta
facial clefts
microcephaly
anomaly of the corpus callosum
ventriculomegaly
tumors
ovarian cysts
pulmonary lesions
gastrointestinal obstructions
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regarding health economics as well as to the individual decision of
each pregnant woman. Expectant mothers should make a deci-
sion only after receiving comprehensive counseling covering the
spectrum of anomalies to be detected and the probability of their
detection as a function of the cut-off values and an explanation of
the safety of diagnostic procedures in expert hands.
In first-trimester screening, the positive predictive values are
low but the method has very high negative predictive values.
Therefore, based on the latest study data of the FMF London for
combined first-trimester screening at a cut-off of 1:100, a sensi-
tivity of 92% and a specificity of 95.4 % in relation to trisomy 21,
the positive predictive value was 7.34% and the negative predic-
tive value was 99.97 %. Similar values apply for trisomies 13 and
18 [39].
Screening using cell-free DNA
Quality parameters
In the initial years prior to and shortly after market introduction,
the majority of studies regarding the sensitivity and specificity of
cfDNA screening were performed in high-risk populations [40 –
46]. Results from routine populations are now available [47 –52].
The small total number and high prevalence in some study po-
pulations makes evaluation in meta-analyses useful. The me-
ta-analysis published by Gil in 2017 [53] including 35 studies
yielded detection rates of 99.7 %, 97.9 %, and 99.0 %, respectively,
for trisomy 21, 18, and 13 and 95.8 % for monosomy X with false-
positive rates of 0.04% for trisomies 21, 18, and 13 and 0.14% for
monosomy X (▶ Table 3). Iwarsson et al. achieved similar results
[52].
In contrast to earlier studies [54], the meta-analysis by Gil in
2017 used a different statistical approach, i. e., bivariate analysis,
as already used in the meta-analysis by Taylor-Phillips [55] and the
dependence of the sensitivity-specificity pairs on different cut-off
values in the individual studies was taken into consideration. The
data pooled from 41 studies were used in a high-risk population
and a normal population (▶ Table 4). Detection rates of 95.9 %
for trisomy 21 (prevalence of trisomy 21 of 1:230), 86.5 % and
77.5 % for trisomy 18 and 13 (prevalence 1:1000 and 1:2000,
respectively) were determined in a normal population. Numerous
studies also include a disproportionate number of tests from later
gestational weeks.
The positive and negative predictive values of a screening
method play an important role in counseling and decision making
prior to screening. It must be taken into consideration that the
prevalence of the anomaly in question has a significant effect on
the positive prediction, even in the case of a high detection rate
and high specificity of a test [56]. Even in the case of complete de-
tection of all cases and a very low false-positive rate, the majority
of screened cases will receive a “false” finding as soon as the prev-
alence is lower than the rate of false-positive findings [57]. This
must be taken into particular consideration when counseling
young pregnant women with a correspondingly low prevalence
of trisomies 21, 18, and 13.
Discrepant findings are usually due to the fact that the major-
ity of cell-free DNA fragments are from the mother and only a
small portion is from the placenta. cfDNA can therefore provide
information regarding placental mosaics and maternal mosaics
and chromosomal anomalies. A vanishing twin can also be the
reason for a false-positive finding when the cfDNA examination is
performed close to the miscarriage event. Therefore, a positive
finding must be confirmed by a diagnostic procedure [58].
None of the currently offered testing methods, both the ran-
dom methods that detect DNA fragments of all chromosomes
and the targeted tests that focus on individual chromosomes, dif-
ferentiates between maternal and placental DNA. The studies
published to date have not been able to show any advantages of
the different approach of SNP-based methods for differentiating
between maternal, placental, and, if available, paternal DNA in re-
lation to detection rates and false-positive rates or the screening
spectrum for genetic anomalies.
The percentage of test failures even after repeated examination
is specified as 0.5 – 6.4 % [59 – 61] (▶ Table 3). A low percentage of
placental DNA (“fetal fraction”), which is positively correlated with
gestational age and the biochemical parameters PAPP-A and PIGF
and negatively correlated with maternal body weight and age and
reproductive measures, is often the cause [62 – 64]. Treatment of
pregnant women with heparin also often results in a reduced
amount of placental DNA [65]. In the group of test failures, a sig-
nificantly increased rate of fetuses with trisomy 13, trisomy 18 or a
triploidy but not trisomy 21 can be observed [47, 62] so that an
early detailed fetal scan and if necessary a diagnostic procedure
are indicated in these cases. The test failures are not included in
most studies. If the failure rate from the first blood sample is taken
into consideration, the modeled detection rates for trisomy 21 are
in the range of 93 – 97% [66]. Test failures due to a fetal fraction of
less than 4% have poor test performance even in the case of a suc-
cessful second analysis. The fetal fraction of every analysis and the
total rate of analyses without a result should be provided by every
lab as a quality criterion. Obese pregnant women must be
informed of a test failure rate of up to 10 % even in the second
trimester [64]. Improvement in diagnostic reliability can be
expected as a result of a greater sequencing depth and new
sequencing techniques such as “paired-end sequencing” [67].
▶ Table 3 Parameters of cfDNA screening (according to Gil [53] and
Revello [62]).
aneuploidy DR % FPR % FF % NR %
Trisomy 21 99.7 0.04 10.7 1.9
Trisomy 18 97.9 0.04 8.6 8.0
Trisomy 13 99.0 0.04 7.0 6.3
Monosomy X 95.8 0.14 10.0 4.1
SCA 100.0 0.04 – –
DR: detection rate, FPR: false-positive rate, SCA: sex chromosome anoma-
lies except for monosomy X, FF: fetal fraction, NR: non-reportables.
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cfDNA screening in multiples
In the case of twin pregnancies, cfDNA screening is more complex
than in singleton pregnancies since the fetuses are either monozy-
gote and thus genetically identical or dizygote in which case it is
highly likely that only one fetus would be affected in the case of an
aneuploidy.
The fetal fraction is usually sufficient in monozygote twins due
to the identical genetic properties of the two fetuses (median
10.1 %) and is comparable with singleton pregnancies, while the
fetal fraction is lower in dizygote twins (median: 7.7 %) [68]. In a
current meta-analysis [53], five studies on twin pregnancies were
examined [68 – 72] (overview in ▶ Table 5). In 24 pregnancies
with trisomy 21 and 1100 pregnancies with euploid fetuses, a DR
of 100 % (95 % CI 95.2 – 100 %) and an FPR of 0 % (95 % CI 0 –
0.003%) were described. Moreover, 14 cases of trisomy 18 were
in the population with 13 being correctly detected and 1 case of
trisomy 13 being incorrectly detected as euploidy. In 4.87% of the
women in this study, the first blood sample did not yield a result.
Similar results were achieved by another prospective study in
which a result could not be obtained in 5.6 % of twin pregnancies
after the first blood draw and in 50% after the second blood draw
while these values were 1.7 % and 32.1 % in the compared popula-
tion of singleton pregnancies [73]. Moreover, this study was able
to show that the rate of test failure in twin pregnancies increases
with an increasing body-mass index (BMI) and is higher after in-
vitro fertilization (IVF) than after natural conception.
In the case of a vanishing twin, cfDNA testing should not be
performed since in many cases an aneuploidy probably caused
the miscarriage of the fetus resulting in false-positive findings
even after a number of weeks [74]. cfDNA is currently not com-
mercially available for higher-order multiple pregnancies. A pri-
mary diagnostic procedure should be considered also in women
with twin pregnancies after IVF and a high BMI since the failure
rates seem to be particularly high here [73].
Screening for trisomy 21 using cfDNA from maternal blood in
twin pregnancies has a comparably high detection rate with an
equally low FPR rate as in singleton pregnancies. Reliable data
regarding the performance of the screening method for trisomy
18 and 13 is currently not available.
Procedure following findings of ultrasound
and first-trimester screening
Fetal anomalies
If isolated or complex fetal anomalies are detected on ultrasound,
the analysis of cfDNA is insufficient and contraindicated due to the
large range of underlying genetic findings. Trisomy 21, 18 or 13 is
the cause in only approximately 60% of fetuses [75, 76]. In addi-
tion to cytogenetically detectable aneuploidies, structural chro-
mosomal anomalies not detectable with cfDNA are found in 7 –
8% of cases with a normal karyogram [77, 78]. Therefore, a diag-
▶ Table 5 Study data regarding the use of cfDNA analysis for trisomy 21 in twin pregnancies (from: Gil 2017 [53]).
cases with trisomy 21 cases without trisomy 21
author total tested as
abnormal
% 95% CI total tested as
abnormal
% 95% CI
Lau (2013) 1 1 100 2.5 – 100 11 0 0 0.0 – 28.5
Huang (2014) 9 9 100 66.4 – 100 180 0 0 0.00 – 2.03
Benachi (2015) 2 2 100 15.8 – 100 5 0 0 0.00 – 52.18
Sarno (2016) 8 8 100 63.1 – 100 409 0 0 0.00 – 0.90
Tan (2016) 4 4 100 39.8 – 100 506 0 0 0.00 – 0.73
Pooled analysis 100 95.2 – 100 0 0 – 0.003
▶ Table 4 Study parameters of cell-free DNA screening in bivariate metaanalyses (according to Taylor-Phillips [55]).
aneuploidy pooled data high-risk population general population
DR % FPR % DR % FPR % PPV % NPV % DR % FPR % PPV % NPV %
Trisomy 21 99.3 0.1 97.3 0.3 91.3 99.9 95.9 0.1 81.6 99.9
Trisomy 18 97.4 0.1 93.0 0.3 84.3 99.9 86.5 0.2 36.6 99.9
Trisomy 13 97.4 0.1 95.0 0.1 87.0 99.7 77.5 0.1 48.8 99.9
DR: detection rate, FPR: false-positive rate, PPV: positive predictive value, NPV: negative predictive value.
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nostic procedure (CVS or amniocentesis) for microscopic karyo-
typing and if necessary chromosomal microarray analysis for
detecting submicroscopic chromosomal anomalies (microdele-
tions and microduplications) should be performed [77, 79]. Inter-
nationally, quick karyotyping (e. g. MLPA or QF-PCR with respect
to the common autosomal trisomies 21, 18, and 13 and the gono-
somal aneuploidies) followed by a chromosomal microarray anal-
ysis is preferred for anomalies for time and cost reasons and con-
ventional cytogenetic karyotyping is not performed [80]. This is
currently not the standard in Germany. In the case of a combina-
tion of anomalies, Next Generation Sequencing technologies
(NGS) such as whole exome sequencing (WES) or whole genome
sequencing (WGS) can be used as the next step [81, 82]. These
technologies are currently still limited to studies [83].
The above-described procedure is also valid when previously
performed cfDNA testing yielded an abnormal result [84].
High-risk group in combined first-trimester screening
In the high-risk group which is defined above cut-off values of
1:10 to 1:100, the spectrum of possible diseases is not limited to
the chromosomal anomalies detectable by cfDNA testing
[18, 36]. A diagnostic procedure must be offered to diagnose the
possible diseases. Averaging all age groups, trisomies 13, 18, and
21 make up approximately 70 % of all chromosomal anomalies
that can be detected by cytogenetic analysis [85, 86]. In the case
of abnormal first-trimester screening, other chromosomal
anomalies of varying clinical relevance were seen in up to 30% of
cases. Alamillo et al. [86] were able to show in over 23 000 preg-
nancies that this was the case in 29.9 % of all abnormal karyo-
grams, with 42% being most common in abnormal first-trimester
screening for trisomies 13 and 18. The Danish Fetal Medicine
Study Group and the Danish Clinical Genetics Study Group [87]
were able to show on the basis of a central country-wide register
including approximately 193 000 pregnancies in Denmark (89 %
of all pregnant women in the report period) that 23.4 % of all rel-
evant pathological karyograms were not trisomies 13, 18, or 21.
The rate of pathological findings increases with the thickness of
the nuchal translucency: 10.4% for an NT thickness between the
95th and 99th percentile and 34.8 % for an NT > 99th percentile.
One study including 11 315 pregnancies showed a rate of chro-
mosomal anomalies of 7.1 % (17% not trisomy 21, 18, or 13) for
an NT between the 95th percentile and 3.4mm. At a size of great-
er than 3.5mm to 11.5mm, the percentage of pathological kar-
yograms increased from 20% to 70% [88]. In 1063 cases with an
increased NT between the 95th percentile and 3.4 mm [89],
pathological karyograms were present in 10% of cases (68 of 611
fetuses), while they were present in 42 % of cases with an NT
greater than 3.4mm (▶ Table 6).
Every increase in the cut-off value between the high-risk group
and the intermediate-risk group results in a reduction in the
detection rate.
Particularly in the case of triploidy and unusual trisomies, the
NT values are closer to the normal distribution while they are
moderately elevated in unbalanced translocations [90]. In one
study, the prevalence of submicroscopic chromosomal anomalies
in the group of fetuses with a nuchal translucency ≥ 3.5mm was
not higher than in fetuses without anomalies detectable on ultra-
sound [91].
▶ Table 6 Rate of chromosomal anomalies depending on first-trimester screening finding and NT measurement. (Publications without inclusion of
chromosomal microarrays).
author criterion n pathological
karyotype (%)
percentage of
all pathol.
karyotypes (%)
trisomies and
SCAs (%)
other
anomalies (%)
percentage of all
other anomalies
Kagan 2006
[88]
NT > 95th perc. 11 315 2168 (19.2) 100 2014 (92.9) 154 (7.1) 100
NT ≥ 3.5mm 4206 1661 (39.4) 76.6 1557 (93.7) 104 (6.3) 67.5
Äyräs 2013
[89]
NT > 95th perc. 1063 224 (21.5) 100 206 (91.9) 18 (8.0) 100
NT ≥ 3.5mm 384 159 (41.4) 71.0 145 (91.2) 14 (8.8) 77.8
Petersen 2014
[87]
NT < 95th perc. 209 257 682 (0.33) 53.4 429 (62.9) 253 (37.1) 84.9
NT ≥ 95th perc. 5966 596 (10.0) 46.6 551 (92.4) 45 (7.6) 15.0
NT ≥ 99th perc. 1362 422 (31.0) 33.0 391 (92.6) 31 (7.3) 10.4
Comb. first-tri-
mester screen-
ing risk ≤ 1:300
185 620 352 (0.19) 31.4 174 (49.4) 178 (50.6) 67.9
> 1:300 8018 770 (9.6) 68.6 686 (89.1) 84 (10.9) 32.1
> 1:100 4002 667 (16.7) 59.4 603 (90.4) 64 (9.6) 24.4
> 1:10 734 378 (51.5) 33.7 365 (96.5) 13 (3.5) 5.0
NT: nuchal translucency, SCA: sex chromosome anomaly. Special features of the studies: Kagan: Population only NT > 95th percentile; only karyograms, no
array-CGH, no data regarding the number of fetuses with anomalies; Äyräs: Population only NT > 95th percentile; only karyograms; no array-CGH; 74 with
anomalies; Petersen: no data regarding the number of fetuses with anomalies; no classification according to karyogram and array-CGH.
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The prevalence of submicroscopic chromosomal structural
anomalies that can only be detected via array-CGH (pathological
CNVs) in populations with an abnormal NT is the subject of
various studies using different NT cut-off values: Lund et al. found
pathological CNVs in 132 fetuses with NT values > 3.5 mm in
12.8 % of cases [92]. Maya et al. [93] used absolute NT values and
found pathological CNVs in 0.9 % of cases for NT values < 3.0mm
with normal cytogenetics, in 1.8 % for NT values between 3.0 and
3.4mm, and in 3.6 % of cases for values > 3.4mm (▶ Table 7).
Tørring et al. [94] showed that PAPP-A is reduced to 0.2 – 0.5
MoM (median 0.34 MoM) in the group of uncommon trisomies
while the NT values were only slightly elevated. f-ßHCG and
PAPP-A were usually significantly reduced, i. e., 0.2 MoM and
0.15 MoM, respectively, in triploidies [95].
The Danish Fetal Medicine Study Group showed that in
the case of an indication for diagnostic procedure with a risk for
trisomy 21 of > 1:300 and for trisomies 13 and 18 of > 1:150 diag-
nostic procedure was offered to approximately 5 % of pregnant
women and a detection rate of > 90 – 95 % for chromosomal
abnormalities was achieved [95]. Another study in a population
with a lower prevalence [39] showed that 75.1 % of chromosomal
abnormalities were detected in the case of an first-trimester
screening risk of > 1:10 in this subgroup (1.4% of examined preg-
nancies). In total, 5.3 % of pregnant women had a cut-off value of
> 1:100. In this group, 88.6 % of anomalies that can be detected
by conventional cytogenetics were found (▶ Table 8).
To limit access to diagnostic procedures and genetic diagnosis
to high-risk groups with NT values ≥ 3.5mm or risks of ≥ 1:10 in
▶ Table 7 Rate of chromosomal anomalies depending on first-trimester screening finding and NT measurement (publications with partial inclusion
of chromosomal microarrays).
author criterion n karyotype and
CMA pathol.
(%)
percen-
tage of all
pathol.
karyo-
types and
CMAs (%)
trisomies 13,
18, 21 and
SCAs (%)
other
aneuploidies
abnormal
CMAs (%)
percentage
of all pathol.
CMAs
(%)
Maya
2017
[93]
NT ≤ 2.9mm 462 8 (1.7) 21.1 2 (25) 2 (25) 4 (50) 40
NT ≥ 3mm 308 30 (9.7) 78.9 20 (66.6) 4 (13.3) 6 (20) 60
NT ≥ 3.5mm 138 19 (13.8) 50.0 13 (68.4) 3 (15.8) 3 (15.7) 30
Vogel
2017
[80]
comb. first-tri-
mester screen-
ing risk > 1:300
575 51 (8.9) 100 28 (54.9) 8 (28.6) 13 (25.4) 1001
comb. first-tri-
mester screen-
ing risk > 1:100
274 35 (12.8) 68.0 23 (65.7) 5 (14.3) 5 (14.2) 38.4
comb. first-
trimester
screening risk
> 1:50
139 23 (16.5) 45.1 20 (86.9) 2 (8.7) 0 (0) 0
CMA: chromosomal microarray, SCA: sex chromosome anomaly. Special features of the studies: Maya: isolated NT, no anomalies. Only pathological CNVs;
Vogel: isolated NT ≤ 3.5mm, no anomalies. Additional CMA findings 6 “susceptibility mutations”, 2 “likely pathogenic”.
1 No data regarding the population with first-trimester screening risk < 1:300.
▶ Table 8 First-trimester screening risk groups and prevalence of chromosomal pathology (data according to Santorum 2017[39]).
first-trimester
screening risk
21,18, 13
n % patho. rate of chromosome anomalies
(Conventional cytogenetics)
percentage of all pathological
chromosome findings
Trisomy
21,18,13
> 1:10 1486 1.4 653 43.9 75.1 526
> 1:50 3699 3.4 742 20.0 85.3 585
> 1:100 5760 5.3 771 13.4 88.6 610
Total n = 108 982; Chromosome anomalies n = 870 (0.8 %); Increase in detected pathologies from >1:10 to > 1:50 n = 89 (10.2% of total pathologies), from
>1:10 to > 1:100 n = 118 (13.6 % of total pathologies).
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first-trimester screening does not seem justified given the risk of
miscarriage of 0.2 % for chorionic villus sampling and 0.1 % for
amniocentesis [96, 97] with the goal of maximum detection rates.
Individual counseling of pregnant women in the case of abnormal
findings in first-trimester screening is of central importance.
Intermediate-risk group and low-risk group in first-
trimester screening
The established spectrum of diseases that can be detected by the
cfDNA screening method is currently still limited to trisomies 21,
18, 13 and gonosomal anomalies. From today’s standpoint, the
use of NIPT analysis can be useful in normal fetuses and in the
case of an intermediate risk according to first-trimester screening,
which is between the cut-off values for the low-risk group and the
high-risk group. In this population, additional ultrasound markers,
such as the nasal bone, ductus venosus and tricuspid regurgita-
tion, have been examined to date. A combination model including
first-trimester screening with a broad spectrum of detectable dis-
eases followed by cfDNA analysis for a certain population can
combine established and new screening methods in a useful way
[98].
If the use of NIPT analysis is limited to a population with a first-
trimester screening risk between 1:10 and 1:1000, the secondary
test method would be used in approximately 20% of cases. 28% of
pregnancies with trisomy 21 are in this risk group [36]. An upper
cut-off value of 1:100 would reduce the intermediate-risk group
to 16 % and increase the high-risk population to 5 %. The rate of
false-positive findings would increase from 0.8 % to 4.6 %, the
rates of detected trisomies 21, 18, and 13 from 86% to 93%, and
the rate of other detected aneuploidies from 44% to 65% [39].
Diagnostic procedures
In the case of abnormal cfDNA screening results, a diagnostic pro-
cedure to verify or falsify the screening finding must be per-
formed [99, 100]. When selecting the diagnostic procedure, it
must be taken into consideration that cfDNA originates largely
from the trophoblast cells and not from the fetus. As in chorionic
villus sampling (CVS), abnormal findings, in particular for trisomy
18, can be based on mosaics about 20% of which represents the
fetus and 80 % the cytotrophoblast cells [58, 101]. CVS should
usually be performed after 11 + 0 weeks for genetic diagnosis.
Given a normal fetus in the detailed ultrasound examination,
amniocentesis is the method of choice starting at 15 + 0 weeks
because the examination is performed using purely fetal cells
and the risk of a mosaic is minimized. Prior to the decision to
perform prenatal diagnostic testing, every pregnant woman
must receive comprehensive information and counseling regard-
ing the information provided by the various genetic lab tests and
the possible risks of diagnostic procedures. The indications for
offering a diagnostic procedure and further clarification during
counseling are:
▪ Fetal malformations [76]
▪ Early growth restriction [23, 102]
▪ Nuchal translucency > 95th percentile
The finding of an increased nuchal translucency thickness is
often seen during initial screening between the 11th and 13th
gestational week and should be an indication for expanding
screening to include additional anatomical and biochemical
parameters or further diagnostic testing by experts [23, 80,
87, 88].
▪ Increased risk according to first-trimester screening
The present studies used various cut-off values. Every increase
in the cut-off value lowers the detection rates both for numeric
and structural chromosomal anomalies as well as for patho-
logical CNVs that are not detected by cfDNA. The resulting
positive rates depend on the quality of first-trimester screen-
ing and the parameters that are used. At a cut-off value of
1:100 for all trisomies, diagnostic procedures were offered to
between 2.1 % and 4.6 % [39, 87, 103] of all pregnant women.
Lowering the cut-off value to 1:300 yielded positive rates of
4.1 % [87] and 10.4 % [39]. The rate of detected anomalies
other than trisomies and aneuploidies of the gonosomes
would increase from 24% to 32% at a lower cut-off value [87]
and that of pathological CNVs from 14% to 25% [80]. Synge-
laki [103] indicates that most retrospective studies do not
detect more than half of these “other” anomalies so that their
detection rates are overestimated.
▪ Abnormal biochemical findings
PAPP-A < 0.2 MoM or fßHCG < 0.2 or > 5 MoM [80, 87, 94]
▪ Abnormal cfDNA screening findings [75, 104]
▪ Wishes of the pregnant woman
The desire to rule out genetic anomalies in fetuses is expressed
even without preceding aneuploidy screening. From a medi-
colegal standpoint, it must be taken into consideration that the
preventative care guidelines still specify a maternal age of 35
or older as a risk factor.
The following genetic lab tests can be performed using the
acquired cells:
▪ Conventional microscopic karyotyping (G-band technique with
a resolution of 7 – 10 million bases)
▪ Fluorescence in situ hybridization (FISH)
▪ Quantitative real-time polymerase chain reaction (qPCR)
▪ Molecular genetic examination of the submicroscopic struc-
ture of the chromosomes via comparative genomic hybridiza-
tion (array-CGH with a significantly higher resolution of
25 000 – 100 000 bases)
▪ Individual gene analyses
In relation to all pregnancies, the incidence of chromosomal
anomalies is 0.44 % [85]. In the case of an abnormal ultrasound
finding, the rate of abnormal karyograms from chorionic villi and
amniotic cells is 2 % with 1.8 % being clinically relevant. 72.7 % of
pathological karyograms are trisomies 13, 18, 21 and anomalies
of the sex chromosomes. Other anomalies are found in 27.3% of
cases [105]. The majority of the over 2100 structural chromosom-
al anomalies (90%) can only be detected via chromosomal micro-
arrays (array-CGH) with a resolution of up to 25 – 100 Kb [106].
The clinical significance of pathological structural changes can be
described in more than 99 % of cases [75]. Microdeletions and
(more rarely) microduplications (pathological “copy number
variations” (CNVs)) are found in 2.5 % of all pregnancies, in
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approximately 1 % of fetuses with normal ultrasound scans, and
slightly more frequently in isolated abnormal serum biochemistry
[77, 107].
In abnormal fetuses (malformation and/or IUGR), pathological
karyograms are found in 14 – 30% of cases [108, 109]. The rate in
the case of NT values > 95th percentile is similar (22– 38%) [89,
91, 110]. In the case of a normal karyogram and abnormal ultra-
sound findings, an array-CGH must be offered. Pathological CNVs
are seen in 6 – 10% of cases [77, 78, 111]. In fetuses with multiple,
particularly dysmorphology-related, symptoms, a targeted search
for monogenic diseases possibly on the basis of relevant databa-
ses must be performed. In the case of dorsonuchal edema and
malformations, over 100 genetic syndromes with single gene mu-
tations such as Noonan syndrome are known [112]. In total, more
than 5000 dysmorphic syndromes are described and particularly
pronounced entities such as skeletal dysplasia can be effectively
visualized on ultrasound [113, 114]. Molecular genetic diagnostic
testing can be performed with Sanger sequencing or NGS-based
panels from any fetal material.
The counseling of pregnant women with respect to the risk of
miscarriage due to the diagnostic procedure should be based on
current large studies that have shown that the miscarriage rate
at expert centers is 1:1000 for amniocentesis and 1:500 for chor-
ionic villus sampling [115 – 117] or does not differ statistically
from the natural miscarriage rate in the particular risk group [96,
97]. A miscarriage rate of 1 % from a prospective randomized
study published in 1986 [118] no longer reflects current knowl-
edge.
In light of the comprehensive genetic diagnostic testing op-
tions, the very low risk associated with diagnostic procedures,
the age-independent prevalence of pathological CNVs, the limita-
tions of cfDNA screening and the fact that only approximately
80 % of chromosomal anomalies are associated with abnormal
ultrasound findings, every pregnant woman should be given the
option of undergoing a diagnostic procedure and microarray anal-
ysis [119, 120].
Screening for rare aneuploidies, gonosomal
aneuploidies, microdeletion syndromes,
and monogenic diseases
Rare aneuploidies
While a number of studies regarding the detection of the most
common trisomies using cfDNA screening of maternal blood are
available, there is minimal data regarding the detection of rarer
aneuploidies, deletions and duplications.
Rare trisomies have a prevalence of 0.3 – 0.8 % [121, 122].
They can be caused by uniparental disomy (UPD) in which case
the fetus inherited both homologous chromosomes from one par-
ent (e. g. trisomy 6, 7, 14, 15, 16) or a placental mosaic can be
present. The latter can be responsible for fetal growth restriction.
In 13% of cases, placental mosaics are representative of an actual
fetal mosaic [123]. Detection rates for the diagnosis of rare aneu-
ploidies based on cfDNA are not provided due to a lack of follow-
up data. The false-positive rates are 0.7% for the total population
and the positive predictive value was only 8 % [122]. Some authors
are calling for the release of the results of rare trisomies due to
their clinical significance [124]. The American College of Medical
Genetics and Genomics (ACMG) recommends not screening for
rare aneuploidies with cfDNA [125].
Triploidy detection via cfDNA is greatly affected by the usually
low placental DNA fraction in maternal blood. Therefore, triploi-
dies are usually not detected [126 – 128] even though the sono-
graphic and biochemical findings are abnormal in first-trimester
screening in up to 90 % of cases [23]. Due to the low placental
DNA fraction, triploidies like trisomy 18 and other anomalies are
very common (3%) in the group of examinations without a result
(no call results) [129]. Following cfDNA without a result, a detailed
ultrasound examination possibly with a diagnostic procedure is
recommended [127].
Sex chromosome aneuploidies, early detection of
fetal sex
The most common sex chromosome aneuploidies (SCAs) are
monosomy 45, X (Ullrich-Turner syndrome), 47, XXX (Triple-X syn-
drome), 47, XXY (Klinefelter syndrome) and 47, XYY (Diplo-Y syn-
drome). The prevalence of SCAs is 0.8– 1% with monosomy 45, X
being most common (approx. 70 %) [122, 130]. The accuracy of
cfDNA screening for the determination of normal fetal sex is
greater than 99%. The diagnostic significance for SCAs is signifi-
cantly lower. A combined evaluation of three studies published
between 2013 and 2015 yielded a detection rate of 89 % for
monosomy 45, X, and between 82% and 90% for the other three
SCAs [131], One meta-analysis found a higher detection rate for
monosomy 45, X (95.8 %) and an FPR of 0.14 %. The detection
rate in this publication is 100 % for other SCAs and the FPR is
0.004% [53]. However, closer analysis of the underlying industry-
sponsored publications shows a high rate of “lost to follow-up”
cases of up to 70% in some of the studies [130]. The information
regarding diagnostic validity is therefore applicable only on a very
limited basis. In particular, the positive predictive value (PPV) for
SCAs seems low. For monosomy 45, X it is approximately 30 %
[131]. A newer, also industry-sponsored, study calculates a PPV
of 70 % for monosomy 45, X [122]. Independent studies show
that the PPV for SCAs is lower: between 38% and 50% for mono-
somy 45, X and between 17% and 50% for 47, XXX, 47, XXY, and
47, XYY [128, 132, 133]. The discordant findings can be due to
placental mosaics but also to a corresponding abnormal maternal
karyotype. Based on 522 SCA cases, Grati et al. showed that a con-
fined placental mosaic (CPM) was present in 122 cases (23.4 %)
while a true fetal mosaic (TFM) was seen in 43 cases (8.2 %). This
relates primarily to fetuses with monosomy 45, X with normal ul-
trasound findings. The positive predictive value of an abnormal
cfDNA analysis is therefore only approximately 53% in this group,
while the PPV would be 98.8 % in the case of an abnormal ultra-
sound finding such as fetal nuchal edema or hygroma [134].
Both in the case of a normal finding regarding fetal sex after
cfDNA and in a pathological finding, sonographic verification of
the fetal sex organs should be performed to rule out developmen-
tal disorders [135]. Due to the ethical problems with respect to
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providing notification of SCAs, the European and American socie-
ties of human genetics currently recommend not providing notifi-
cation of such findings after cfDNA [136]. The American College
of Medical Genetics and Genomics recommends comprehensive
counseling regarding the issues prior to cfDNA screening [125].
According to the Genetic Diagnostics Act, notification of the
fetal sex may not be provided prior to 14+0 weeks. However, in
individual cases, advance determination of the sex is important.
Particularly in the case of adrenogenital syndrome (AGS), it is im-
portant to determine the sex before seven weeks: Virilization is to
be prevented in female fetuses by administering steroids but the
side effects and effectiveness are a topic of discussion [137]. The
sex can be determined even at this early time with cfDNA analysis.
The test systems focus on the detection of SRY or DYS14 [138]. If
these cannot be detected, treatment would be initiated. A further
use is the determination of the sex in X-chromosome diseases
such as Duchenne muscular dystrophy. Also in the case of an
unclear sex on ultrasound and the differential diagnoses clitoris
hypertrophy vs. hypospadias, the use of cfDNA analysis could
become more important.
Microdeletions/microduplications
Microdeletions and microduplications (pathological copy number
variations (CNVs)) are very small structural anomalies that cannot
be detected by conventional microscopic chromosome analysis.
They are diagnosed in 1 – 1.7 % of pregnancies with normal find-
ings and are thus much more common than trisomy 21 in younger
pregnant women [139]. Reliable diagnosis of pathological CNVs
can only be achieved from fetal samples via array-CGH (see the
section “Diagnostic procedures”). However, many of the over
2100 known CNVs are extremely rare [106]. Therefore, the prev-
alence of the most common microdeletion, i. e., microdeletion
22q11.2 (DiGeorge syndrome), is 1:4000 to 1:1000. Additional
microdeletions, such as Cri-du-Chat syndrome (microdeletion
5p15), have rates of significantly less than 1:10 000, in some cases
less than 1:100 000 [140]. In contrast to the trisomies, the rate of
microdeletions is independent of maternal age. For several years,
the providers of cfDNA screening tests have been using various
techniques to screen for pathological CNVs in addition to the
most common trisomies. These changes are difficult to detect
with cfDNA due to their size of less than 5 – 7 megabases (Mb).
At present, only CNVs > 3 MB, probably even only > 6 Mb can be
detected by cfDNA [140, 141]. The majority of companies limit
their offer to the most common larger microdeletions, such as
22q11.2 (DiGeorge syndrome), 15q (Prader Willi/Angelman syn-
drome) and 5p15 (Cri-du-Chat syndrome). Therefore, in the best
case 0.1 – 11 % of pathological CNVs are currently detected by
cfDNA [120, 140, 142, 143].
The publications of various providers regarding cfDNA screen-
ing for microdeletions are based largely on retrospective evalua-
tions of existing serum samples of fetuses with postnatally detect-
ed diseases and allow only partial calculation of the true
diagnostic value since there are high “lost to follow-up” rates of
up to 70 % of cases or no information regarding the populations
is provided [122, 144 – 146]. Therefore, reliable detection rates
cannot be calculated from the available data. A retrospective
proof of concept study yielded a theoretical detection rate of
74 % for all examined CNVs [147]. Given a false-positive rate for
the entire examined population of > 1% and low rates of anoma-
lies, combining the available data yields low positive predictive
values between 4 % and 5 % for most pathological CNVs [140].
According to this, the majority of abnormal findings would be
false-positive.
An independent study examining the cfDNA tests of various
providers finds a positive predictive value of 0 % for microdele-
tions and a high number of test failures (“non-reportables”) for
these anomalies (65%) [148].
A relevant ethical problem is the possible detection of mater-
nal CNVs or maternal tumors based on cfDNA screening for
pathological CNVs [121, 129]. Direct diagnosis via array-CGH
from chorionic villi or amniotic fluid eliminates this problem
because only placental or fetal DNA is analyzed.
The guidelines of multiple societies state that cfDNA screening
for pathological CNVs cannot be recommended [125, 136, 149,
150].
Determination of fetal blood group
Fetal blood group determination is important particularly in the
case of a positive antibody test and rhesus D-negative pregnant
women. If the fetus is rhesus D-negative, immunological fetal an-
emia cannot occur. Chitty et al. showed that the detection rate for
rhesus D via cfDNA after 12 weeks is over 99.7% [151]. Fetal blood
group antigens Kell, C, c, E and e can also be determined via cell-
free DNA [152]. Based on these results, there is a discussion as
to whether the fetal rhesus D factor should be determined in rhe-
sus-negative women and the administration of anti-D should be
limited to women with rhesus D-positive fetuses.
Detection of monogenic diseases
The spectrum of cfDNA testing was already expanded to include
monogenic diseases such as achondroplasia and thanatophoric
dysplasia in 2007. In Great Britain, cfDNA detection of these two
diseases, Apert syndrome and paternal mutations of cystic fibrosis
have already been approved by the NHS. Since the cfDNA test is
possible beginning in the 9th gestational week, an advantage
could be the very early exclusion of recurrence [138]. The number
of potentially detectable diseases far exceeds those named above
and primarily includes additional autosomal-dominant diseases,
such as tuberous sclerosis, as well as several autosomal-recessive
entities, such as autosomal-recessive polycystic kidney disease
[153].
First-trimester screening for maternofetal
disease screening
The use of cell-free DNA from the placenta for the prediction of
placenta-based diseases has also been studied [154, 155]. How-
ever, no relevant dose change of placental cfDNA in pregnancies
that later developed placenta-based pregnancy complications
could be found in studies performed at 11+0 – 13+6 weeks [156 –
159]. Combination with biochemical markers [160] or uterine
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Doppler measurements [161] also did not improve prediction
rates.
With the key publication entitled “Turning the pyramid of prena-
tal care” [3], Nicolaides expanded genetically oriented first-trime-
ster screening to include early screening for maternofetal diseases.
Maternofetal diseases are more common than fetal genetic anoma-
lies by a factor of approximately 10 and can generally be prevented.
Models for early risk prediction have been developed for the preg-
nancy complications preeclampsia [162 – 165], fetal growth restric-
tion [166], miscarriage and stillbirth [167], gestational diabetes
[168, 169], fetal macrosomy and preterm delivery [170].
The present model shows that it is possible in principle to screen
for the main problems of pregnancy already between 11+0 and 13+6
weeks and to develop prediction models for multifactorial diseases
on the basis of individual risk factors [171, 172]. However, the per-
formance of early prediction tests in pregnancy has been only mod-
erate to date and validation studies are not available in most cases
[173, 174].
Preeclampsia (PE)
For example, successful development has been seen for the early
prediction of PE [175] with good test performance [162, 164, 176]
and confirmation by external validation in an unselected population
[177]. The breakthrough regarding prevention was achieved with
the reduction in the incidence of PE via the early administration of
low-dose aspirin: in the ASPRE study pregnant women were
screened for PE with the FMF algorithm at 11+ 0 – 13+ 6 weeks. In
the high-risk group (risk > 1:100), the administration of ASS
(150mg/day, beginning at 11 –14 weeks) reduced the incidence of
PE < 37 weeks by 62% (P =0.004) and PE < 34 weeks by 82% [178].
Newer biophysical methods make it possible to determine the
pulse wave velocity and the augmentation index for detailed eval-
uation of the maternal pulse wave. Early prediction of the PE risk
in the first trimester is also the focus of scientific interest here
[179, 180].
In the case of a previous Cesarean section, early screening
between the 11th and 14th weeks for indications of scar defects
[181, 182] and primarily for signs of an increased risk of placenta
accreta [183] is extremely important for early presentation at a
prenatal center. Current studies by Timor-Tritsch show advanta-
ges of early detection of scar implantation, as early as 8 – 10
weeks [184] and allow the option of early minimally invasive treat-
ment [185].
First-trimester screening is no longer used only for aneuploidy
screening. The expansion of the first-trimester scan to include
maternofetal medicine will become increasingly important since
the effectiveness of preventative measures will benefit greatly
from an early start and thus early risk detection.
Outlook
Screening tests using cell-free DNA after detailed ultrasound ex-
amination of the fetus at the end of the first trimester and expert
counseling regarding the spectrum of diagnostic options can be
helpful for pregnant women desiring extensive exclusion of triso-
mies.
Primary cfDNA screening performed as early as possible carries
the risk that a normal cfDNA screening finding will result in possi-
ble structural anomalies or other genetic anomalies not being de-
tected until 20 weeks or not at all. The updated consensus state-
ment of the ISUOG expresses the concern that primary cfDNA
screening in the low-risk population could have a negative effect
both on the quality of counseling prior to cfDNA testing and on
diagnostic ultrasound imaging in the subsequent weeks [186].
The acceptance of cfDNA screening tests is largely due to the
fear of complications from diagnostic procedures [187].
The expansion of screening to include additional anomalies
with a largely low prevalence further complicates counseling.
A main problem of current cfDNA tests is the dominance of
maternal DNA fragments. All counting methods cannot differenti-
ate between maternal and placental DNA. SNP-based methods
are based on a comparison of maternal, fetal, and paternal nu-
cleotide sequences but this basic advantage has not yet been
able to be verified.
Methods for isolating individual fetal cells [188, 189] or examin-
ing microRNA [190, 191] as well as the isolation of trophoblast cells
from cervical smears [187, 192] or from embryonic cells after coe-
locentesis [193] have been described in small study series. Faster
and cheaper sequencing techniques could provide new diagnostic
possibilities even in the case of small cell numbers or fragments.
The indispensable and overdue inclusion of chromosomal mi-
croarrays and the possibility of whole exome sequencing (WES)
[83] in prenatal genetic diagnostic testing and the new data re-
garding the low complication rates of diagnostic procedures
should be reason to reevaluate genetic analyses.
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